KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to 102.21%.

  • Ionis Pharmaceuticals' EBITDA Margin rose 88800.0% to 102.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.07%, marking a year-over-year increase of 110500.0%. This contributed to the annual value of 67.37% for FY2024, which is 224600.0% down from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' EBITDA Margin stood at 102.21%, which was up 88800.0% from 50.29% recorded in Q2 2025.
  • Ionis Pharmaceuticals' EBITDA Margin's 5-year high stood at 50.29% during Q2 2025, with a 5-year trough of 136.95% in Q4 2022.
  • In the last 5 years, Ionis Pharmaceuticals' EBITDA Margin had a median value of 63.92% in 2022 and averaged 60.41%.
  • Per our database at Business Quant, Ionis Pharmaceuticals' EBITDA Margin skyrocketed by 3400800bps in 2021 and then crashed by -1870900bps in 2022.
  • Over the past 5 years, Ionis Pharmaceuticals' EBITDA Margin (Quarter) stood at 50.14% in 2021, then tumbled by -373bps to 136.95% in 2022, then surged by 99bps to 1.89% in 2023, then plummeted by -2493bps to 48.91% in 2024, then crashed by -109bps to 102.21% in 2025.
  • Its last three reported values are 102.21% in Q3 2025, 50.29% for Q2 2025, and 111.59% during Q1 2025.